Nuclear factor‐κB (nf‐κB) is frequently expressed in lung cancer and preneoplastic lesions

Nuclear factor‐κB (NF‐κB), a key transcription factor thought to play a major role in carcinogenesis, regulates many important signaling pathways involved in tumor promotion. Although NF‐κB can be activated in lung cancer cell lines by tobacco exposure, there have been no studies of the expression of NF‐κB in lung cancer pathogenesis.

[1]  H. Lee,et al.  Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  I. Wistuba,et al.  Precursors to Pulmonary Neoplasia , 1998, Advances in anatomic pathology.

[3]  Debajit K. Biswas,et al.  Epidermal growth factor-induced nuclear factor κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells , 2000 .

[4]  M. Karin,et al.  The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. , 2004, Cancer letters.

[5]  B. Aggarwal,et al.  Nuclear factor-kappaB: a friend or a foe in cancer? , 2004, Biochemical pharmacology.

[6]  N. Perkins,et al.  Transcriptional cross talk between NF-kappaB and p53. , 1999, Molecular and cellular biology.

[7]  B. Aggarwal,et al.  Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. , 2004, Journal of immunology.

[8]  S. Bozinovski,et al.  Acquired somatic mutations in the molecular pathogenesis of COPD. , 2003, Trends in pharmacological sciences.

[9]  Shishir Shishodia,et al.  Molecular targets of dietary agents for prevention and therapy of cancer. , 2006, Biochemical pharmacology.

[10]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[11]  L. Lessard,et al.  NF-kappa B nuclear localization and its prognostic significance in prostate cancer. , 2003, BJU international.

[12]  M. Merville,et al.  NF-κB2/p100 induces Bcl-2 expression , 2003, Leukemia.

[13]  B. Aggarwal,et al.  Cyclooxygenase (COX)-2 Inhibitor Celecoxib Abrogates TNF-Induced NF-κB Activation through Inhibition of Activation of IκBα Kinase and Akt in Human Non-Small Cell Lung Carcinoma: Correlation with Suppression of COX-2 Synthesis1 , 2004, The Journal of Immunology.

[14]  D. Baltimore,et al.  Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. , 1986, Cell.

[15]  T. Dang,et al.  Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel , 2005, Clinical Cancer Research.

[16]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[17]  L. Lessard,et al.  NF‐κB nuclear localization and its prognostic significance in prostate cancer , 2003 .

[18]  Marshall W. Anderson,et al.  Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies , 2005, BMC Cancer.

[19]  A. Garg,et al.  Nuclear factor-kappa B as a predictor of treatment response in breast cancer. , 2003, Current opinion in oncology.

[20]  J. Gills,et al.  Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. , 2005, Carcinogenesis.

[21]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[22]  B. Aggarwal,et al.  Nuclear factor-kappaB: a friend or a foe in cancer? , 2004, Biochemical pharmacology.

[23]  Michael Karin,et al.  NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.

[24]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[25]  M. Roth,et al.  Celecoxib Decreases Ki-67 Proliferative Index in Active Smokers , 2006, Clinical Cancer Research.

[26]  B. Aggarwal,et al.  Chemopreventive Agents Induce Suppression of Nuclear Factor‐κB Leading to Chemosensitization , 2002, Annals of the New York Academy of Sciences.

[27]  L. Lessard,et al.  Expression of NF‐κB in prostate cancer lymph node metastases , 2004 .

[28]  Robert E. Brown,et al.  Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis , 2005, Modern Pathology.

[29]  Rinat Abramovitch,et al.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.

[30]  J. Mulshine,et al.  The potential contributions of chronic inflammation to lung carcinogenesis. , 2003, Clinical lung cancer.

[31]  K M Kerr.  Pulmonary preinvasive neoplasia. , 2001, Journal of clinical pathology.

[32]  B. Aggarwal,et al.  Curcumin: Getting Back to the Roots , 2005, Annals of the New York Academy of Sciences.

[33]  Ronald Simon,et al.  Tissue microarrays in drug discovery , 2003, Nature Reviews Drug Discovery.

[34]  M. Karin,et al.  The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer , 2004 .

[35]  I. Wistuba,et al.  Smoking molecular damage in bronchial epithelium , 2002, Oncogene.

[36]  J. Minna,et al.  Focus on lung cancer. , 2002, Cancer cell.

[37]  G. Dong,et al.  Expression of a Dominant-Negative Mutant Inhibitor-κBα of Nuclear Factor-κB in Human Head and Neck Squamous Cell Carcinoma Inhibits Survival, Proinflammatory Cytokine Expression, and Tumor Growth in Vivo , 1999 .

[38]  H. Stünzi,et al.  Tumours of the lung. , 1974, Bulletin of the World Health Organization.

[39]  Liang Cheng,et al.  Nuclear Factor-κB Is Constitutively Activated in Prostate Cancer In vitro and Is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate , 2004, Clinical Cancer Research.

[40]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[41]  L. Lessard,et al.  Expression of NF-kappaB in prostate cancer lymph node metastases. , 2004, The Prostate.

[42]  P. Cassidy,et al.  Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  N. Perkins,et al.  Transcriptional Cross Talk between NF-κB and p53 , 1999, Molecular and Cellular Biology.

[44]  H. Thaler,et al.  Chemotherapy Induces the Expression of Cyclooxygenase-2 in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[45]  M. Karin,et al.  Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression , 2004 .

[46]  H. Lee,et al.  Nuclear Factor-κB Activation Correlates with Better Prognosis and Akt Activation in Human Gastric Cancer , 2005, Clinical Cancer Research.

[47]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[48]  J. Gera,et al.  Downstream effectors of oncogenic ras in multiple myeloma cells. , 2003, Blood.

[49]  M. Grafe,et al.  Transcriptional Regulation of the BCL-X Gene by NF-κB Is an Element of Hypoxic Responses in the Rat Brain , 2004, Neurochemical Research.

[50]  Andrew J. Dannenberg,et al.  Regulation of Cyclooxgenase-2 mRNA Stability by Taxanes , 2003, Journal of Biological Chemistry.

[51]  M. Karin,et al.  Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. , 2004, Cancer cell.

[52]  J. Reynolds,et al.  NF-&kgr;B Activation in Esophageal Adenocarcinoma: Relationship to Barrett's Metaplasia, Survival, and Response to Neoadjuvant Chemoradiotherapy , 2004, Annals of surgery.

[53]  Bharat B. Aggarwal,et al.  Nuclear factor-&kgr;B as a predictor of treatment response in breast cancer , 2003 .

[54]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[55]  W. Westra.  Early glandular neoplasia of the lung , 2000, Respiratory research.

[56]  C. Y. Wang,et al.  TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. , 1996, Science.

[57]  David Baltimore,et al.  Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism , 1986, Cell.

[58]  J. Ajani,et al.  Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  B. Aggarwal,et al.  Nuclear factor-kappaB: the enemy within. , 2004, Cancer cell.

[60]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[61]  A. Pardee,et al.  Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[62]  B. Aggarwal,et al.  Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. , 2004, Cancer research.